Sight Sciences, Inc.SGHTEarnings & Financial Report
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Allegro Investment Fund, L.P. | 8.30% | 4.0M | — | 2023-12-01 |
| UBS Group AG directly and on behalf of certain subsidiaries. | 5.90% | 2.9M | — | 2024-02-07 |
| NOS. OF ABOVE PERSONS | 4.20% | 2.1M | ▼ -5.30pp | 2024-11-14 |
| D1 Capital Partners L.P. | 0.00% | 82.7K | — | 2024-01-10 |
Insider Transactions
Net 90d: −$311.8K · buys $0 / sells $311.8KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | James Rodberg | Chief Financial Officer | Sell (open market) | 7.2K | $3.55 | $25.7K |
| 2026-04-06 | HAYDEN JEREMY B. | Chief Legal Officer | Sell (open market) | 13.8K | $3.55 | $48.9K |
| 2026-04-02 | Alison Bauerlein | Chief Operating Officer | Sell (open market) | 25.9K | $3.48 | $90.0K |
| 2026-04-02 | David Badawi | Chief Technology Officer | Sell (open market) | 8.2K | $3.48 | $28.4K |
| 2026-04-01 | Paul Badawi | President and CEO | Sell (open market) | 29.2K | $3.70 | $108.2K |
| 2026-04-01 | Brenton Taylor | EVP, Operations & R&D | Sell (open market) | 2.9K | $3.70 | $10.6K |
| 2026-02-19 | David Badawi | Chief Technology Officer | Option exercise | 21.3K | $0.23 | $4.9K |
| 2026-02-03 | Alison Bauerlein | Chief Operating Officer | Grant | 127.5K | $0.00 | $0 |
| 2026-02-03 | HAYDEN JEREMY B. | Chief Legal Officer | Grant | 115.9K | $0.00 | $0 |
| 2026-02-03 | David Badawi | Chief Technology Officer | Grant | 64.9K | $0.00 | $0 |
1–10 of 13
Page 1 / 2